Compass Therapeutics
Clinical trials sponsored by Compass Therapeutics, explained in plain language.
-
New hope for cancer patients when immunotherapy fails?
Disease control CompletedThis early-stage study tested a new drug called CTX-471, given alone or with another immunotherapy (pembrolizumab), in 100 adults with advanced cancers like lung cancer, melanoma, or head and neck cancer that had stopped responding to standard PD-1/PD-L1 inhibitors. The main goal…
Phase: PHASE1 • Sponsor: Compass Therapeutics • Aim: Disease control
Last updated May 26, 2026 10:46 UTC
-
New hope for Tough-to-Treat colon cancer?
Disease control CompletedThis study tested an experimental drug called CTX-009 in 49 adults with metastatic colorectal cancer that had worsened after two or three prior treatments. The goal was to see if the drug could shrink tumors or stop them from growing. While not a cure, it aims to give patients mo…
Phase: PHASE2 • Sponsor: Compass Therapeutics • Aim: Disease control
Last updated May 26, 2026 10:44 UTC